Search

Your search keyword '"Department of Neonatology [Tours]"' showing total 3 results
Start Over Author "Department of Neonatology [Tours]"
3 results on '"Department of Neonatology [Tours]"'

1. Risk factors for bronchiolitis hospitalization in infants: A French nationwide retrospective cohort study over four consecutive seasons (2009-2013)

Author

Jean-Christophe Rozé, Jean-Michel Hascoet, Jean-François Magny, Pierre-Henri Jarreau, Brigitte Fauroux, Elie Saliba, Michaël Schwarzinger, Sommeil-Vigilance-Fatigue et Santé Publique (VIFASOM (URP_7330)), Institut de Recherche Biomédicale des Armées (IRBA)-Université Paris Cité (UPCité), Unité Pédiatrique de Ventilation Non Invasive et de Sommeil [CHU Necker Enfants-Malades], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Maternité Régionale Adolphe Pinard [Nancy], Développement, Adaptation et Handicap. Régulations cardio-respiratoires et de la motricité (DevAH), Université de Lorraine (UL), Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier universitaire de Nantes (CHU Nantes), Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Translational Health Economics Network [Paris] (THEN), Sorbonne Université (SU), The present study was supported by AbbVie France. Translational Health Economics (THEN) was responsible for data collection, preparation, and validation with external sources of information. THEN received payment from AbbVie for these activities. Writing charges were funded by AbbVie France, and AbbVie approved the decision to submit the paper for publication, but the corresponding author was ultimately responsible for submitting the manuscript for publication., HASCOET, JEAN-MICHEL, Service d'assistance respiratoire et sommeil de l'enfant [CHU Necker], Sommeil-Vigilance-Fatigue et Santé Publique (VIFASOM - EA 7330), Institut de Recherche Biomédicale des Armées (IRBA)-Université de Paris (UP), Regional Maternity [Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Université de Lorraine (UL), Université de Paris (UP), Department of Neonatal Medicine of Port-Royal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Cochin [AP-HP], Neonatal Intensive Care Unit of Port-Royal [Paris], Department of Neonatology [Paris], Department of Neonatology [Nantes], Department of Neonatology [Tours], Hôpital Gatien de Clocheville [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, Université Paris Diderot - Paris 7 (UPD7), Université Sorbonne Paris Cité (USPC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, and Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)

Subjects
Male, Pediatrics, Pulmonology, Epidemiology, Physiology, Cell Transplantation, Comorbidity, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Families, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Morphogenesis, Blood and Lymphatic System Procedures, Birth Weight, 030212 general & internal medicine, Children, education.field_of_study, Multidisciplinary, Congenital Heart Defects, Hospitals, 3. Good health, Hospitalization, Physiological Parameters, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Bronchiolitis, Medicine, Female, France, Seasons, Infants, Research Article, medicine.medical_specialty, Down syndrome, Science, Population, Cardiology, Surgical and Invasive Medical Procedures, 03 medical and health sciences, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, 030225 pediatrics, Internal medicine, Congenital Disorders, medicine, Humans, Birth Defects, education, Transplantation, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, Omphalocele, business.industry, Body Weight, Infant, Biology and Life Sciences, Retrospective cohort study, medicine.disease, Health Care, Bronchopulmonary dysplasia, Age Groups, Health Care Facilities, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Medical Risk Factors, People and Places, Respiratory Infections, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Population Groupings, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Developmental Biology, Stem Cell Transplantation
Abstract

International audience; Objectives: Large studies are needed to update risk factors of bronchiolitis hospitalization. We performed a nationwide analysis of hospitalization rates for bronchiolitis over four consecutive bronchiolitis seasons to identify underlying medical disorders at risk of bronchiolitis hospitalization and assess their frequency.Methods: Data were retrieved from the French National Hospital Discharge database. Of all infants discharged alive from maternity wards from January 2008 to December 2013 in France (N = 3,884,791), we identified four consecutive cohorts at risk of bronchiolitis during the seasons of 2009–2010 to 2012–2013. The main outcome was bronchiolitis hospitalization during a season. Individual risk factors were collected.Results: Among infants, 6.0% were preterm and 2.0% had ≥1 chronic condition including 0.2% bronchopulmonary dysplasia (BPD) and 0.2% hemodynamically significant congenital heart disease (HS-CHD). Bronchiolitis hospitalization rates varied between seasons (min: 1.26% in 2010–2011; max: 1.48% in 2012–2013; p

Published
2020

2. The role of erythropoietin to prevent red blood cell transfusion in a 2018-2020 two-center cohort of preterm infants.

Author

Bailly N, Brat R, and Favrais G

Subjects
Humans, Infant, Newborn, Male, Female, Recombinant Proteins therapeutic use, Cohort Studies, Gestational Age, Erythropoietin therapeutic use, Erythrocyte Transfusion, Infant, Premature
Abstract

Background: Treatment with recombinant human erythropoietin (rHu-EPO) modestly prevented packed red blood cell transfusions (pRBCTs) in preterm infants in studies performed several years ago. In France, some neonatal units stopped using rHu-EPO, while others continued. The aim of this study was to explore the role of rHu-EPO in the prevention of pRBCTs in a recent cohort of preterm infants., Materials and Methods: Preterm infants who met rHu-EPO indications and were hospitalised between 2018 and 2020 in two neonatal units -one that did not use rHu-EPO and another that did- were eligible. Data about the neonatal history, rHu-EPO and iron treatments and pRBCT indications and volumes were collected. Infants exposed and not exposed to rHu-EPO were compared in univariate and multivariate analyses using backward logistic regression and Cox proportional hazards regression., Results: A total of 257 patients exposed to rHu-EPO and 285 patients who were not exposed were included. Three profiles emerged. In the infants with a gestational age <28 weeks, the cumulative pRBCT volume/kg was similar regardless of rHu-EPO exposure (mean difference -2.8 mL, 95% confidence interval -16.1, 10.5, p=0.68). In the infants born between 28 and 30 weeks, a late pRBCT was prevented in the rHu-EPO group (single pRBCT: no rHu-EPO 22.1% vs rHu-EPO 8%, p=0.003). However, rHu-EPO was not independently associated with avoidance of this pRBCT. Finally, the need for pRBCT was low in the infants born after 30 weeks of gestation, making rHu-EPO treatment futile. In contrast, early iron supplementation was revealed to be critical in preventing pRBCT., Discussion: No benefit of rHu-EPO in preventing pRBCT was observed in our cohort. The place of rHu-EPO in future requires careful consideration of the population concerned, adjustment of the therapeutic schedule and evolution of the indications for pRBCT.

Published
2024
Full Text
View/download PDF

3. The use of flumazenil in a neonate.

Author

Richard P, Autret E, Bardol J, Soyez C, Barbier P, Jonville AP, and Ramponi N

Subjects
Benzodiazepines antagonists & inhibitors, Humans, Infant, Newborn, Recurrence, Apnea drug therapy, Benzodiazepines adverse effects, Flumazenil therapeutic use
Abstract

Side effects of benzodiazepines used during pregnancy are described in a neonate. Recurrent apnea was reversed after administration of flumazenil, a specific antagonist of benzodiazepines.

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results